Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Extensive Stage Small Cell Lung Cancer (ES-SCLC), confirmed by a laboratory test on tumor tissue.
• People who have not yet received any treatment for ES-SCLC.
• People whose cancer can be measured on scans using standard criteria (confirm with trial site).
• People aged 18 or older.
• People who are reasonably active and able to care for themselves, with only mild limitations on daily activity (confirm with trial site).
• People who are able to understand and sign a written consent form.
• People willing to provide stored tumor tissue samples (if available) and blood samples for research purposes.
• People whose blood counts and organ function fall within acceptable ranges, based on blood tests done within 14 days before joining — including healthy levels of white blood cells, platelets, red blood cells, kidney function, liver function, and blood clotting (confirm specific values with trial site).
• People living with HIV who are on effective treatment and have had an undetectable viral load within the past 6 months.
• People who have had a previous or separate cancer, as long as that cancer and its treatment are unlikely to interfere with this trial's results (confirm with trial site).

Who may not be able to join:

• People who are pregnant or breastfeeding.
• People who are not willing to use effective contraception or abstain from sexual activity during the trial and for 120 days after the last dose of study medication.
• People who have brain or nervous system involvement from the cancer that is causing symptoms, involves a growth of 1.5 cm or larger, was recently treated with radiation to the brain (within 7 days of joining), or has spread to the lining around the brain.
• People whose scans show the cancer is growing into or wrapping around major blood vessels (such as the aorta or large arteries of the chest), invading major organs (such as the heart, windpipe, or oesophagus), or creating a significant risk of a tunnel forming between the oesophagus and the airways or chest cavity.
• People whose scans show the cancer is squeezing or narrowing major blood vessels, or where there are cavities or areas of tissue breakdown in the tumour that the doctor considers to carry a high bleeding risk.
• People who have had major surgery or serious injury within 28 days before joining, or who are planning major surgery within 28 days of the first dose.
• People who have a history of bleeding problems or significant bleeding events within 4 weeks before joining — including coughing up blood (half a teaspoon or more of fresh blood), or nosebleeds involving fresh blood flow (not just bloody discharge).
• People currently using blood-thinning or anti-clotting medications in a way that has not been stable before joining (confirm with trial site).
• People who have had serious heart problems within the past 12 months, including unstable chest pain (angina), heart attack, significant heart failure, dangerous abnormal heart rhythms, or unstable blood vessel conditions.
• People who have had a blood clot in an artery, a serious blood clot in a vein, a mini-stroke or stroke, or a hypertensive crisis within the past 12 months.
• People who have had varicose veins in the oesophagus or stomach, severe ulcers, wounds that won't heal, or serious gastrointestinal bleeding within the past 6 months.
• People who have had a hole or tear in the digestive tract, a serious blockage in the bowel, or extensive bowel removal surgery within the past 6 months.
• People whose blood pressure remains high (systolic at or above 150 mmHg or diastolic at or above 100 mmHg) even after taking blood pressure medication.
• People with a specific type of irregular heartbeat pattern on an ECG (QTc interval above 480 milliseconds).
• People who have an active autoimmune disease or lung disease that required significant medication (such as immune-suppressing drugs or steroids above a low dose) within the past 2 years.
• People who have had a serious infection requiring hospitalisation within the past 4 weeks, or who are currently on treatment for an active infection (other than antiviral therapy for hepatitis B or C) within the past 2 weeks.
• People who have uncontrolled fluid build-up around the lungs, heart, or in the abdomen that is causing symptoms.
• People with a history of lung inflammation (non-infectious) that required steroid treatment, or who currently have a chronic lung scarring condition.
• People with a history of inflammatory bowel disease, such as Crohn's disease, ulcerative colitis, or ongoing chronic diarrhoea.
• People who already have significant nerve damage in their hands or feet (Grade 2 or above, confirm with trial site).
• People who have received a live vaccine within 28 days before joining.
• People who have a known allergy to any of the study medications or their ingredients.
• People with a serious medical or psychiatric condition that, in the doctor's opinion, could prevent them from completing the treatment as required.
• People who are currently participating in another therapeutic clinical trial, unless prior approval has been granted by the coordinating organisation.

Important: Always verify eligibility with the trial site directly before applying.